Constitutive production of interleukin‐6 and immunologic features in cardiac myxomas

Jourdan, Michel; Bataille, Régis; Seguin, J; Zhang, Xue Guang; Chaptal, P.A.; Klein, Bernard

doi:10.1002/art.1780330313

Cited by 155 publications

(56 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We reached similar conclusions when studying IL-6 in patients with cardiac myxoma (10). This is of importance since IL-6 production in vivo can at present be only estimated from serum IL-6 levels, which actually reflect a minor portion of the IL-6 produced in vivo, i.e., the portion not absorbed by either cell surface receptors or the kidneys.…”

supporting

confidence: 71%

C‐reactive protein levels as a direct indicator of interleukin‐6 levels in humans in vivo

Bataille¹,

Klein²

1992

Arthritis & Rheumatism

Self Cite

147

View full text Add to dashboard Cite

LETTERSpoints require special attention when evaluating the role of these cells in RA: whether they accumulate in rheumatoid lesions and whether they express a specific family of y/S receptor. Considering the first point, available data again show conflicting results. Kjeldsen-Kragh et a1 (5). Wood et al (6), and Chaouni et a1 (7) found similar proportions of y/S T cells in SF and PB of RA patients. In contrast, our results (1) and those of Rkme et al (3) and Smith et a1 (4) show higher numbers of y/S T cells in the synovial compartment than in PB of RA patients. Reasons for these disparities remain obscure, but it seems obvious that further investigations of larger numbers of RA patients in the early stages of disease, as well as of comparison groups of patients with other chronic inflammatory arthropathies, are needed.As far as the expression of y/S T cell receptor subpopulations is concerned, most studies show that ylS T cells from the rheumatoid synovial compartment do not express V,9 gene products, which contrasts with $8 T cells from the PB (1,4,6,8). Furthermore, results of both phenotype and messenger RNA analysis suggest a preferential expression of V,1 gene products (1,4,6,8). We agree with Kjeldsen-Kragh et a1 that the phenotype sTCS1-, BB3-,TiyA-could be explained by several combinations of rearrangements between S gene segments and y gene seg-

show abstract

supporting

confidence: 71%

C‐reactive protein levels as a direct indicator of interleukin‐6 levels in humans in vivo

Bataille¹,

Klein²

1992

Arthritis & Rheumatism

Self Cite

147

View full text Add to dashboard Cite

show abstract

“…Whereas this high proliferation rate in extramedullary sites has already been documented 19 little is known about this in reactive plasmacytosis. 20 However, the high rate of proliferation observed in reactive plasmacytosis is consistent with their fast appearance and disappearance during the clinical course of infectious diseases. Moreover, in extramedullary sites and in reactive plasmacytosis we observed elevated serum values of lactic dehydrogenase (results not shown) reflecting an important cells loss and suggesting a weaker resistance of these plasma cells to apoptosis.…”

Section: Discussionmentioning

confidence: 72%

Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy

et al. 1999

View full text Add to dashboard Cite

Multiple myeloma (MM) is a malignancy characterized by a very slow proliferation of malignant plasma cells leading to their accumulation within the bone marrow. This suggests that resistance to apoptosis may play a critical role both in the pathogenesis and resistance to treatment of MM. Bcl-2 is a key protein for the regulation of apoptosis. However, it has been shown that this protein also regulates the state of proliferation. In the current study, we show that malignant plasma cells from both the bone marrow and peripheral blood express high levels of Bcl-2 and are slowly proliferating cells. In contrast, myeloma cells from extramedullary sites (ie pleural effusion, ascitis, mammary and gastric plasmacytoma) express Bcl-2 weakly while being highly proliferative. Normal non-dividing bone marrow plasma cells express high levels of Bcl-2 protein. In contrast, four highly proliferative reactive plasmacytosis express weak levels of Bcl-2. We conclude that there is an inverse correlation between Bcl-2 expression and the proliferation rate of both normal and malignant plasma cells. These data may be explained by the double function of Bcl-2, ie its well known function as an anti-apoptotic molecule and its intriguing function as an inhibitory molecule of cell proliferation.

show abstract

“…Pheochromocytoma and liposarcoma are examples of IL-6-producing tumours with associated thrombocytosis (Nagasawa et al, 1990;Suzuki et al, 1991). In some other diseases, such as rheumatoid arthritis and cardiac myxoma, and in burmed patients, the elevation of serum IL-6 levels has also been demonstrated (Holt et al, 1991;Jourdan et al, 1991;Nijsten et al, 1991).…”

Section: Discussionmentioning

confidence: 99%

Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma

Nakano

Chahinian²,

Shinjo³

et al. 1998

Br J Cancer

115

View full text Add to dashboard Cite

SummaryThe relationship between interleukin 6 (IL-6) levels and clinical parameters was studied in 25 patients with malignant pleural mesothelioma. The serum levels of IL-6, C-reactive protein, a,-acid glycoprotein and fibrinogen were significantly higher in mesothelioma than in lung adenocarcinoma with cytology-positive pleural effusion. Serum IL-6 levels correlated with the levels of the acute-phase proteins. We demonstrated a high incidence of thrombocytosis (48%) and a significant correlation between platelet count and the serum IL-6 level. The level of IL-6 in the pleural fluid of patients with mesothelioma was significantly higher than in the pleural fluid of patients with adenocarcinoma, and was about 60-1400 times higher than in the serum. However, even higher levels of IL-6 in the pleural fluid and of thrombocytosis were found in patients with tuberculous pleurisy. These results indicate that large amounts of IL-6 from the pleural fluid of patients with mesothelioma leak into the systemic circulation and induce clinical inflammatory reactions. These profiles are not specific to mesothelioma as similar profiles are found in patients with tuberculous pleurisy. However, the detection of a markedly increased level of IL-6 in pleural fluid argues against a diagnosis of adenocarcinoma.

show abstract

Constitutive production of interleukin‐6 and immunologic features in cardiac myxomas

Cited by 155 publications

References 20 publications

C‐reactive protein levels as a direct indicator of interleukin‐6 levels in humans in vivo

C‐reactive protein levels as a direct indicator of interleukin‐6 levels in humans in vivo

Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy

Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma

Contact Info

Product

Resources

About